pfenex.investorroom.com

Welcome

Pfenex is a clinical-stage biotechnology company developing and commercializing high value and difficult to manufacture proteins. Our initial focus is on biosimilar therapeutics and our lead product is PF582, a biosimilar to Lucentis (ranibizumab). Our patented protein production platform, Pfenex Expression Technology. Pfenex is leveraging its technology platform for its own product pipeline. And for scientists seeking reagents for research use. Aug 17, 2015. Aug 13, 2015. Jul 29, 2015. Aug 17, 2015.

http://pfenex.investorroom.com/

OVERVIEW OF pfenex.investorroom.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

12

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR PFENEX.INVESTORROOM.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

July

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Saturday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 4.0 out of 5 with 10 reviews

5 star

3

4 star

4

3 star

3

2 star

0

1 star

0

Hey there! Start your review of pfenex.investorroom.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

6.5 seconds

FAVICON PREVIEW

16x16

CONTACTS AT PFENEX.INVESTORROOM.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

12

SSL

EXTERNAL LINKS

39

SITE IP

64.78.159.10

LOAD TIME

6.516 sec

SCORE

6.2

PAGE TITLE

Welcome | pfenex.investorroom.com Reviews

<META> DESCRIPTION

Pfenex is a clinical-stage biotechnology company developing and commercializing high value and difficult to manufacture proteins. Our initial focus is on biosimilar therapeutics and our lead product is PF582, a biosimilar to Lucentis (ranibizumab). Our patented protein production platform, Pfenex Expression Technology. Pfenex is leveraging its technology platform for its own product pipeline. And for scientists seeking reagents for research use. Aug 17, 2015. Aug 13, 2015. Jul 29, 2015. Aug 17, 2015.

<META> KEYWORDS

1 toggle navigation

2 menu

3 product pipeline

4 platform technology

5 senior management

6 board of directors

7 our partners

8 careers

9 newsroom

10 blog

CONTENT

Page content here

KEYWORDS ON PAGE

toggle navigation,menu,product pipeline,platform technology,senior management,board of directors,our partners,careers,newsroom,blog,our biosimilars,our approach,our products,our vaccines,our position,investors,welcome,corporate governance,news releases

SERVER

Apache

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Welcome | pfenex.investorroom.com Reviews

https://pfenex.investorroom.com

Pfenex is a clinical-stage biotechnology company developing and commercializing high value and difficult to manufacture proteins. Our initial focus is on biosimilar therapeutics and our lead product is PF582, a biosimilar to Lucentis (ranibizumab). Our patented protein production platform, Pfenex Expression Technology. Pfenex is leveraging its technology platform for its own product pipeline. And for scientists seeking reagents for research use. Aug 17, 2015. Aug 13, 2015. Jul 29, 2015. Aug 17, 2015.

INTERNAL PAGES

pfenex.investorroom.com

1

Welcome

http://pfenex.investorroom.com/welcome

Pfenex is a clinical-stage biotechnology company developing and commercializing high value and difficult to manufacture proteins. Our initial focus is on biosimilar therapeutics and our lead product is PF582, a biosimilar to Lucentis (ranibizumab). Our patented protein production platform, Pfenex Expression Technology. Pfenex is leveraging its technology platform for its own product pipeline. And for scientists seeking reagents for research use. Oct 26, 2016. Oct 19, 2016. Oct 3, 2016. Oct 26, 2016.

2

Pfenex Inc. - Investors - News Releases

http://pfenex.investorroom.com/news-releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below. Get News Alerts by Email. Oct 26, 2016. Pfenex To Report Third Quarter 2016 Results and Provide Business Update on Wednesday, November 9, 2016. Oct 19, 2016. Pfenex Inc. Announces Formation of Scientific Advisory Board. Oct 3, 2016. Aug 8, 2016. Pfenex Inc. (NYSE MKT: PFNX), a clinical-stag...

3

Financial Reporting

http://pfenex.investorroom.com/stock-information

809 - $8.56. 579 - $17.33. Quote data delayed by at least 15 minutes.

4

Pfenex Inc. Awarded HHS Contract Valued At Up To $143.5 Million For The Advanced Development Of Next Generation Anthrax Vaccine - Aug 17, 2015

http://pfenex.investorroom.com/2015-08-17-Pfenex-Inc-Awarded-HHS-Contract-Valued-At-Up-To-143-5-Million-For-The-Advanced-Development-Of-Next-Generation-Anthrax-Vaccine

Pfenex Inc. Awarded HHS Contract Valued At Up To $143.5 Million For The Advanced Development Of Next Generation Anthrax Vaccine. Contract administered by the Biomedical Advanced Research and Development Authority focused on Pfenex's Px563L. Monday, August 17, 2015 (8:00am). Aug 17, 2015. Pfenex Inc. (NYSE MKT: PFNX), announced today it has signed a five year, cost plus fixed fee contract valued at up to $143.5 million. Pfenex has used, and intends to continue to use, its Investor Relations website ( http...

5

Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 - Jul 29, 2015

http://pfenex.investorroom.com/2015-07-29-Pfenex-To-Report-Second-Quarter-2015-Results-and-Provide-Business-Update-on-Thursday-August-13-2015

Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015. Wednesday, July 29, 2015 (8:30am). July 29, 2015. Pfenex Inc. (NYSE MKT: PFNX) announced today that its second quarter 2015 financial results will be released on Thursday, August 13, 2015. Before the open of market. At 8:30 am Eastern Time. Pfenex has used, and intends to continue to use, its Investor Relations website ( http:/ pfenex.investorroom.com. Pfenex Inc. is a clinical-stage biotechnology c...

UPGRADE TO PREMIUM TO VIEW 7 MORE

TOTAL PAGES IN THIS WEBSITE

12

LINKS TO THIS WEBSITE

pfenex.com

Our Approach – Pfenex

http://www.pfenex.com/biosimilars

Financials & Filings. We believe that biosimilars are the future of affordable healthcare. Our unique protein production platform and bioanalytic approach allows us to produce quality biosimilar products efficiently and effectively to increase patient access at a lower cost. We have an established expertise in the development of biosimilars and seek to increase access to lower-cost, high-quality biologic drugs. Learn more about the potential cost savings and safety of these innovative products here.

pfenex.com

Our Partners – Pfenex

http://www.pfenex.com/about-us/our-partners

Financials & Filings. Biomedical Advanced Research and Development Authority (BARDA). National Institute of Allergy and Infectious Diseases. Serum Institute of India Ltd. Merck & Co. Inc.

pfenex.com

Our Approach – Pfenex

http://www.pfenex.com/biosimilars/our-approach

Financials & Filings. We believe that biosimilars are the future of affordable healthcare. Our unique protein production platform and bioanalytic approach allows us to produce quality biosimilar products efficiently and effectively to increase patient access at a lower cost. We have an established expertise in the development of biosimilars and seek to increase access to lower-cost, high-quality biologic drugs. Learn more about the potential cost savings and safety of these innovative products here.

pfenex.com

Blog Posts – Pfenex

http://www.pfenex.com/about-us/blog-posts

Financials & Filings. Statement on Introduction of CREATES Act to Support Access to Reference Product. Pfenex applauds Senators Patrick Leahy (D-VT), Chuck Grassley (R-IA), Amy Klobuchar (D-MN), and Mike Lee (R-UT) for their efforts introducing the Creating and Restoring Equal Access to Equivalent Samples Act ( CREATES Act. Statement on Inclusion of Section 11, Biological Product Innovation in the FDA & NIH Workforce Authorities Modernization Act. Pfenex’s full statement on Thursday’s hearing is below:.

pfenex.com

Our Products – Pfenex

http://www.pfenex.com/vaccines/products

Financials & Filings. Our innovative platform technologies provide the capability to proactively create a national reserve of vaccines in a cost-effective and efficient manner unparalleled by our competitors. This has positioned us as a primary partner with the U.S. government for the development of critical anthrax and malaria vaccines. FULLY FUNDED BY THE. SDI rPA based Anthrax Vaccine 2nd Generation. RPA based Anthrax Vaccine. RPA based Anthrax Vaccine. Development controlled by the US Government.

pfenex.com

Position – Pfenex

http://www.pfenex.com/our-position-2

Financials & Filings. Pfenex is uniquely situated to deliver a robust pipeline of biosimilars and vaccines to patients globally. We are committed to working with regulatory agencies, legislators and our partners to create and foster a supportive regulatory environment that ensures patient access to needed therapeutics and vaccines. Including CVS Health, Express Scripts, Kaiser Permanente, Pharmaceutical Care Management Association, and Rite Aid as well as the Federal Trade Commission (FTC). Pfenex Statem...

pfenex.com

Newsroom – Pfenex

http://www.pfenex.com/news-room

Financials & Filings. The State of the Biosimilars Industry. Will the approval of Inflectra be a biosimilar adoption tipping point? A Perspective on the Medicare Part B Drug Experiment. Pfenex Chief Business Officer Patrick Lucy to Present Corporate Overview at BIO2016. The Biosimilars Council: Why Trade Organizations Are Key for Biosimilars. Pfenex Chief Medical Officer Hubert Chen to Share Clinical Expertise at Biosimilars & Biobetters Congress. Pfenex CEO and Biosimilars Council Chair Dr. Bert Lia...

pfenex.com

Site Map – Pfenex

http://www.pfenex.com/site-map

Financials & Filings. The State of the Biosimilars Industry. Statement on Introduction of CREATES Act to Support Access to Reference Product. Pfenex applauds Senators Patrick Leahy (D-VT), Chuck Grassley (R-IA), Amy Klobuchar (D-MN), and Mike Lee (R-UT) for their efforts introducing the Creating and Restoring Equal Access to Equivalent Samples Act (CREATES Act). The Act supports access to reference product for biosimilar development, thereby expediting patient access to valuable medicines. Biosim...

pfenex.com

Product Pipeline – Pfenex

http://www.pfenex.com/about-us/product-pipeline

Financials & Filings. Pfenex is a leading-edge biologics company driven by the desire to provide access to safe, effective, affordable products to market. We have the highest-quality protein production and bioanalytic technology platform approach that allows us to create biosimilars in a highly efficient manner from concept to commercialization. See our complete product pipeline below. BRANDED REFERENCE DRUGS (2015). Biologic Lucentis marketed by Hoffmann-La Roche and Novartis AG. Biologic Cimzia markete...

UPGRADE TO PREMIUM TO VIEW 30 MORE

TOTAL LINKS TO THIS WEBSITE

39

SOCIAL ENGAGEMENT

pages/Pfenex-Inc/105908276167776

pfenex

OTHER SITES

pfenergy.es

PLAST & FOAM ENERGY

P and F ENERGY. P and F ENERGY es una empresa pionera en España, en el mercado de la Geotermia. Diseñado por SSII.

pfenergy.it

Giacca Spidi Offerta Spedizione E Reso Gratuiti - Shift Italia Negozi Spedizione Gratuita In 24 Ore - Reso Sempre Gratuito

Moto MX / Enduro. Moto MX / Enduro. Le novità di aprile. Spidi combat evo ii h2out jacket giacche urban nero abbigliamento uomo,spidi. Spidi dogma jacket giacche urban nero abbigliamento uomo,spidi jeans. Spidi combat field h2out jacket giacche urban verde abbigliamento uomo,Spidi. Spidi combat field h2out jacket giacche urban blu abbigliamento uomo,spidi. Spidi 4way h2out giacche urban grigio abbigliamento uomo,pantaloni spidi on. Spidi combat evo ii h2out jacket giacche urban verde nero abbigliamento.

pfenergycenter.blogspot.com

Re: Energy

Wednesday, August 5, 2015. The final Clean Power Plan is here. On Monday, August 3, 2015, the Environmental Protection Agency (EPA) announced the final Clean Power Plan. The rule that will help limit carbon pollution from fossil fuel power plants. What does it mean for Pennsylvania? In Pennsylvania, those targets are:. Each affected facility meets a rate-based standard. 1,305 lbs/MWh for coal, gas (steam turbine), or other fossil fuel. 771 lbs/MWh for natural gas combined cycle (NGCC). For example, DEP k...

pfenerji.com

PF ENERJİ,FUATYEŞİLYURT

PF ENERJİ İNŞAAT SEKTÖRÜNDEKİ ELEKTRİK TAAHHÜT İŞLERİNİN,PROJE AŞAMASINDAN SON AŞAMASINA KADAR ENERJİ İLE İLGİLİ OLAN BÜTÜN SÜREÇLERİNİ,. DÜZENLİ,TEKNİK ŞARTNAMELERE VE YÖNETMELİKLERE UYGUN OLARAK HİZMET KALİTESİNDEN VE MALZEME KALİTESİNDEN ASLA ÖDÜN VERMEDEN İŞ GÜVENLİĞİNİ ÖN PLANDA TUTARAK VE YILLARDIR BU SEKTÖRDE BİR ÇOK PROJEYE ATTIĞI İMZALARDAN KENDİNE TECRÜBE EDİNEREK. YENİ,DİNAMİK,GÜÇLÜ,VE HERŞEYİN MÜKEMMEL OLMASI İÇİN PF ENERJİ 2012 YILINDA KURULMUŞTUR. 21° 10°.

pfenex.com

Home | Pfenex | Innovative solutions for global health

Financials & Filings. We are a clinical stage development and licensing biotechnology company focused on leveraging our. Pfenex Expression Technology platform to develop and improve protein therapies for unmet patient needs. Learn about Pfenex Expression Technology and our other state of the art production capabilities. Learn about our advanced pipeline of therapeutic equivalents, vaccines, biologics, and biosimilars.

pfenex.investorroom.com

Welcome

Pfenex is a clinical-stage biotechnology company developing and commercializing high value and difficult to manufacture proteins. Our initial focus is on biosimilar therapeutics and our lead product is PF582, a biosimilar to Lucentis (ranibizumab). Our patented protein production platform, Pfenex Expression Technology. Pfenex is leveraging its technology platform for its own product pipeline. And for scientists seeking reagents for research use. Aug 17, 2015. Aug 13, 2015. Jul 29, 2015. Aug 17, 2015.

pfenex.staging.wpengine.com

Pfenex – Innovative solutions for global health through biosimilars.

Financials & Filings. We are an innovative, leading-edge company focused on bringing biosimilars to market. Learn more about our approach to biosimilars. Our analytical approach to biosimilars allows us to provide patients access to safe, effective, and affordable products. Learn how this supports our robust product pipeline. Our innovative technology and ability to rapidly create a stockpile of essential vaccines has positioned us as a primary partner with the US Government. Pfenex supports the issuance...

pfenfam.com

www.pfenfam.com

Notice: This domain name expired on 07/13/15 and is pending renewal or deletion. This domain registration expired on 07/13/2015. Do you own this domain? Use of this Site is subject to express Terms of Use. By using this Site, you signify that you agree to be bound by these Terms of Use. Which were last revised on.

pfeng.biz

Doména je registrována na serverech Web4U s.r.o.

Doména je registrována na serverech Web4U s.r.o. Tato doména byla zaregistrována na serverech společnosti Web4U s.r.o., vlastník domény zde zatím nezobrazil žádný obsah. Web4U s.r.o., vše pro vaši internetovou prezentaci.

pfeng.cc

p.feng

My name is Peiying Feng. I also go by Cathy sometimes. I'm an artist and designer who loves creating work that merges different mediums and disciplines. I also love challenges and am always willing to try something new. Some of the work I do includes web design, graphic design, game design, interactive installations, data visualizations and more. In my spare time, I enjoy reading, paintballing and being a unicorn. Interested in working together? Try The World Canada.

pfeng.com

Price Request - BuyDomains

Url=' escape(document.location.href) , 'Chat367233609785093432', 'toolbar=0,scrollbars=0,location=0,statusbar=0,menubar=0,resizable=0,width=640,height=500');return false;". Need a price instantly? Just give us a call. Toll Free in the U.S. We can give you the price over the phone, help you with the purchase process, and answer any questions. Get a price in less than 24 hours. Fill out the form below. One of our domain experts will have a price to you within 24 business hours. United States of America.